Evidence map›Paper›PMID 37522740›Full record

ArticleBlood advances2023

Significance of E-lesions in Hodgkin lymphoma and the creation of a new consensus definition: a report from SEARCH.

Eline A M Zijtregtop, Jamie Zeal, Monika L Metzger, Kara M Kelly, Christine Mauz-Koerholz, Stephan D Voss, Kathleen McCarten, Jamie E Flerlage, Auke Beishuizen

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 3 countries.

Eline A M ZijtregtopDepartment of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Jamie ZealDepartment of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN.
Monika L MetzgerDepartment of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN.
Kara M KellyDepartment of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.
Christine Mauz-KoerholzDepartment of Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Giessen, Giessen, Germany.
Stephan D VossDepartment of Radiology, Boston Children's Hospital Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-2092-2219
Kathleen McCartenImaging and Radiation Oncology Core-Rhode Island, Lincoln, RI.ORCID 0009-0002-2580-4171
Jamie E FlerlageDepartment of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN.ORCID 0000-0002-4182-9355
Auke BeishuizenDepartment of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.ORCID 0000-0002-6482-1823
St. Jude Children's Research Hospital · USBoston Children's Hospital · USErasmus MC - Sophia Children’s Hospital · NLJustus-Liebig-Universität Gießen · DEPrincess Máxima Center · NLRhode Island Department of Environmental Management · USRoswell Park Comprehensive Cancer Center · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The International Staging Evaluation and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) seeks to provide an appropriate, universal differentiation between E-lesions and stage IV extranodal disease in Hodgkin lymphoma (HL). A literature search was performed through the PubMed and Google Scholar databases using the terms "Hodgkin disease," and "extranodal," "extralymphatic," "E lesions," "E stage," or "E disease." Publications were reviewed for the number of participants; median age and age range; diagnostic modalities used for staging; and the definition, incidence, and prognostic significance of E-lesions. Thirty-six articles describing 12 640 patients met the inclusion criteria. Most articles reported staging per the Ann Arbor (72%, 26/36) or Cotswolds modification of the Ann Arbor staging criteria (25%, 9/36), and articles rarely defined E-lesions or disambiguated "extranodal disease." The overall incidence of E-lesions for patients with stage I-III HL was 11.5% (1330/11 602 unique patients). Available stage-specific incidence analysis of 3888 patients showed a similar incidence of E-lesions in stage II (21.2%) and stage III (21.9%), with E-lesions rarely seen with stage I disease (1.1%). E-lesions likely remain predictive, but we cannot unequivocally conclude that identifying E-lesions in HL imparts prognostic value in the modern era of the more selective use of targeted radiation therapy. A harmonized E-lesion definition was reached based on the available evidence and the consensus of the SEARCH working group. We recommend that this definition of E-lesion be applied in future clinical trials with explicit reporting to confirm the prognostic value of E-lesions.

Indexed as

Hodgkin DiseaseAdolescentAdultHumansNeoplasm StagingPrognosisSystematic Reviews as Topic

Identifiers

PMID37522740
PMCPMC10589789
OpenAlexW4385406236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.